{"id":182282,"date":"2023-10-16T04:41:47","date_gmt":"2023-10-16T08:41:47","guid":{"rendered":"https:\/\/www.eldiario.net\/portal\/?p=182282"},"modified":"2023-10-16T04:41:47","modified_gmt":"2023-10-16T08:41:47","slug":"inti-presenta-farmaco-de-doble-accion-antitumoral","status":"publish","type":"post","link":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/","title":{"rendered":"INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral"},"content":{"rendered":"<p>Droguer\u00eda INTI, representante exclusivo de la l\u00ednea Merck en Bolivia, realiz\u00f3 el lanzamiento del primer f\u00e1rmaco contra el c\u00e1ncer colorectal, de cabeza y de cuello.<br \/>\nSe trata de Erbitux, un medicamento de doble acci\u00f3n antitumoral que tiene el principio activo del Cetuximab, anticuerpo monoclonal que act\u00faa bloqueando lo que se conoce como el Receptor de Factor de Crecimiento Epid\u00e9rmico (EGFR), una prote\u00edna que acelera el crecimiento de un tumor y aumenta la posibilidad de hacer met\u00e1stasis.<br \/>\nPara dar a conocer las propiedades del f\u00e1rmaco, el laboratorio organiz\u00f3 el 1er. Simposio sobre el C\u00e1ncer Colorrectal Metast\u00e1sico (CCRm) y de C\u00e1ncer de Cabeza y Cuello (CCC) en La Paz, Cochabamba y Santa Cruz, dirigido a m\u00e9dicos especialistas en esta patolog\u00eda.<br \/>\nLos disertantes internacionales con amplia experiencia en la investigaci\u00f3n y cl\u00ednica fueron Federico Esteso, m\u00e9dico onc\u00f3logo, subjefe del \u00c1rea de Tumores Digestivos en el Instituto Alexander Fleming (IAF) de Argentina y David Pereira, m\u00e9dico especialista en Oncolog\u00eda Cl\u00ednica y Radioterapia, investigador y miembro del Comit\u00e9 de \u00c9tica e Investigaci\u00f3n del Instituto de Oncolog\u00eda Angel H. Roffo de Argentina.<br \/>\nEl evento se realiz\u00f3 en instalaciones del hotel Renova, ante una importante presencia de m\u00e9dicos.<\/p>\n<div id='gallery-1' class='gallery galleryid-182282 gallery-columns-3 gallery-size-medium'><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon landscape'>\n\t\t\t\t<a href='https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/equipo-inti-merck\/'><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"211\" src=\"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck-300x211.jpg\" class=\"attachment-medium size-medium\" alt=\"\" aria-describedby=\"gallery-1-182283\" srcset=\"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck-300x211.jpg 300w, https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck-768x540.jpg 768w, https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck-696x489.jpg 696w, https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck.jpg 1000w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-182283'>\n\t\t\t\tEQUIPO INTI MERCK.\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon landscape'>\n\t\t\t\t<a href='https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/lic-gustavo-gonzalez-jefe-de-producto-merck-bolivia-lic-juan-carlos-gutierrez-gerente-de-unidad-de-negocios-drogueria-inti-s-a-dr-federi\/'><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"178\" src=\"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Lic.-Gustavo-Gonzalez-Jefe-de-Producto-Merck-Bolivia-Lic.-Juan-Carlos-Gutierrez-Gerente-de-Unidad-de-Negocios-Drogueria-INTI-S.A.-Dr.-Federi-300x178.jpg\" class=\"attachment-medium size-medium\" alt=\"\" aria-describedby=\"gallery-1-182284\" srcset=\"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Lic.-Gustavo-Gonzalez-Jefe-de-Producto-Merck-Bolivia-Lic.-Juan-Carlos-Gutierrez-Gerente-de-Unidad-de-Negocios-Drogueria-INTI-S.A.-Dr.-Federi-300x178.jpg 300w, https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Lic.-Gustavo-Gonzalez-Jefe-de-Producto-Merck-Bolivia-Lic.-Juan-Carlos-Gutierrez-Gerente-de-Unidad-de-Negocios-Drogueria-INTI-S.A.-Dr.-Federi-768x455.jpg 768w, https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Lic.-Gustavo-Gonzalez-Jefe-de-Producto-Merck-Bolivia-Lic.-Juan-Carlos-Gutierrez-Gerente-de-Unidad-de-Negocios-Drogueria-INTI-S.A.-Dr.-Federi-696x413.jpg 696w, https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Lic.-Gustavo-Gonzalez-Jefe-de-Producto-Merck-Bolivia-Lic.-Juan-Carlos-Gutierrez-Gerente-de-Unidad-de-Negocios-Drogueria-INTI-S.A.-Dr.-Federi.jpg 1000w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-182284'>\n\t\t\t\tGUSTAVO GONZ\u00c1LEZ, JEFE DE PRODUCTO MERCK BOLIVIA; JUAN CARLOS GUTI\u00c9RREZ, GERENTE DE UNIDAD DE NEGOCIOS DROGUER\u00cdA INTI ; FEDERICO ESTESO, ESPECIALISTA EN ONCOLOGIA &#8211; ARGENTINA; GUILLERMO SEMINARIO, DIRECTOR COMERCIAL CONO SUR MERCK, Y RANDY LINARES, GERENTE REGIONAL LP. INTI.\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon landscape'>\n\t\t\t\t<a href='https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/presentacion-medica\/'><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"194\" src=\"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Presentacion-medica-300x194.jpg\" class=\"attachment-medium size-medium\" alt=\"\" aria-describedby=\"gallery-1-182285\" srcset=\"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Presentacion-medica-300x194.jpg 300w, https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Presentacion-medica-768x495.jpg 768w, https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Presentacion-medica-696x449.jpg 696w, https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Presentacion-medica.jpg 1000w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-182285'>\n\t\t\t\tUN ASPECTO DE LA PRESENTACI\u00d3N DE ERBITUX.\n\t\t\t\t<\/figcaption><\/figure>\n\t\t<\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>Droguer\u00eda INTI, representante exclusivo de la l\u00ednea Merck en Bolivia, realiz\u00f3 el lanzamiento del primer f\u00e1rmaco contra el c\u00e1ncer colorectal, de cabeza y de cuello. Se trata de Erbitux, un medicamento de doble acci\u00f3n antitumoral que tiene el principio activo del Cetuximab, anticuerpo monoclonal que act\u00faa bloqueando lo que se conoce como el Receptor de [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":182283,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[40],"tags":[],"class_list":["post-182282","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sociales"],"acf":{"antetitulo":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral - El Diario - Bolivia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral - El Diario - Bolivia\" \/>\n<meta property=\"og:description\" content=\"Droguer\u00eda INTI, representante exclusivo de la l\u00ednea Merck en Bolivia, realiz\u00f3 el lanzamiento del primer f\u00e1rmaco contra el c\u00e1ncer colorectal, de cabeza y de cuello. Se trata de Erbitux, un medicamento de doble acci\u00f3n antitumoral que tiene el principio activo del Cetuximab, anticuerpo monoclonal que act\u00faa bloqueando lo que se conoce como el Receptor de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/\" \/>\n<meta property=\"og:site_name\" content=\"El Diario - Bolivia\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/eldiario.bolivia\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-16T08:41:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"703\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jeanette\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@eldiario_net\" \/>\n<meta name=\"twitter:site\" content=\"@eldiario_net\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jeanette\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/\"},\"author\":{\"name\":\"Jeanette\",\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/#\\\/schema\\\/person\\\/8b67770232aae58f106f1b9207b37de6\"},\"headline\":\"INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral\",\"datePublished\":\"2023-10-16T08:41:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/\"},\"wordCount\":229,\"publisher\":{\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Equipo-Inti-Merck.jpg\",\"articleSection\":[\"Sociales\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/\",\"url\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/\",\"name\":\"INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral - El Diario - Bolivia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Equipo-Inti-Merck.jpg\",\"datePublished\":\"2023-10-16T08:41:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Equipo-Inti-Merck.jpg\",\"contentUrl\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Equipo-Inti-Merck.jpg\",\"width\":1000,\"height\":703,\"caption\":\"EQUIPO INTI MERCK.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/2023\\\/10\\\/16\\\/inti-presenta-farmaco-de-doble-accion-antitumoral\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/#website\",\"url\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/\",\"name\":\"El Diario - Decano de la prensa nacional\",\"description\":\"El Diario - Decano de la prensa nacional\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/#organization\",\"name\":\"El Diario - Decano de la prensa nacional\",\"url\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/logo_ED.jpg\",\"contentUrl\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/logo_ED.jpg\",\"width\":272,\"height\":52,\"caption\":\"El Diario - Decano de la prensa nacional\"},\"image\":{\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/eldiario.bolivia\\\/\",\"https:\\\/\\\/x.com\\\/eldiario_net\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/#\\\/schema\\\/person\\\/8b67770232aae58f106f1b9207b37de6\",\"name\":\"Jeanette\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3ea2118a5f7dad2b7138b1187a6b7ee55f160b9968b66013c3a3ef39dd7e5798?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3ea2118a5f7dad2b7138b1187a6b7ee55f160b9968b66013c3a3ef39dd7e5798?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3ea2118a5f7dad2b7138b1187a6b7ee55f160b9968b66013c3a3ef39dd7e5798?s=96&d=mm&r=g\",\"caption\":\"Jeanette\"},\"sameAs\":[\"https:\\\/\\\/www.eldiario.net\\\/portal\"],\"url\":\"https:\\\/\\\/www.eldiario.net\\\/portal\\\/author\\\/jeanette\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral - El Diario - Bolivia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/","og_locale":"es_ES","og_type":"article","og_title":"INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral - El Diario - Bolivia","og_description":"Droguer\u00eda INTI, representante exclusivo de la l\u00ednea Merck en Bolivia, realiz\u00f3 el lanzamiento del primer f\u00e1rmaco contra el c\u00e1ncer colorectal, de cabeza y de cuello. Se trata de Erbitux, un medicamento de doble acci\u00f3n antitumoral que tiene el principio activo del Cetuximab, anticuerpo monoclonal que act\u00faa bloqueando lo que se conoce como el Receptor de [&hellip;]","og_url":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/","og_site_name":"El Diario - Bolivia","article_publisher":"https:\/\/www.facebook.com\/eldiario.bolivia\/","article_published_time":"2023-10-16T08:41:47+00:00","og_image":[{"width":1000,"height":703,"url":"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck.jpg","type":"image\/jpeg"}],"author":"Jeanette","twitter_card":"summary_large_image","twitter_creator":"@eldiario_net","twitter_site":"@eldiario_net","twitter_misc":{"Escrito por":"Jeanette","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/#article","isPartOf":{"@id":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/"},"author":{"name":"Jeanette","@id":"https:\/\/www.eldiario.net\/portal\/#\/schema\/person\/8b67770232aae58f106f1b9207b37de6"},"headline":"INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral","datePublished":"2023-10-16T08:41:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/"},"wordCount":229,"publisher":{"@id":"https:\/\/www.eldiario.net\/portal\/#organization"},"image":{"@id":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/#primaryimage"},"thumbnailUrl":"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck.jpg","articleSection":["Sociales"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/","url":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/","name":"INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral - El Diario - Bolivia","isPartOf":{"@id":"https:\/\/www.eldiario.net\/portal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/#primaryimage"},"image":{"@id":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/#primaryimage"},"thumbnailUrl":"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck.jpg","datePublished":"2023-10-16T08:41:47+00:00","breadcrumb":{"@id":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/#primaryimage","url":"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck.jpg","contentUrl":"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/10\/Equipo-Inti-Merck.jpg","width":1000,"height":703,"caption":"EQUIPO INTI MERCK."},{"@type":"BreadcrumbList","@id":"https:\/\/www.eldiario.net\/portal\/2023\/10\/16\/inti-presenta-farmaco-de-doble-accion-antitumoral\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.eldiario.net\/portal\/"},{"@type":"ListItem","position":2,"name":"INTI presenta f\u00e1rmaco de doble acci\u00f3n antitumoral"}]},{"@type":"WebSite","@id":"https:\/\/www.eldiario.net\/portal\/#website","url":"https:\/\/www.eldiario.net\/portal\/","name":"El Diario - Decano de la prensa nacional","description":"El Diario - Decano de la prensa nacional","publisher":{"@id":"https:\/\/www.eldiario.net\/portal\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.eldiario.net\/portal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.eldiario.net\/portal\/#organization","name":"El Diario - Decano de la prensa nacional","url":"https:\/\/www.eldiario.net\/portal\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.eldiario.net\/portal\/#\/schema\/logo\/image\/","url":"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/07\/logo_ED.jpg","contentUrl":"https:\/\/www.eldiario.net\/portal\/wp-content\/uploads\/2023\/07\/logo_ED.jpg","width":272,"height":52,"caption":"El Diario - Decano de la prensa nacional"},"image":{"@id":"https:\/\/www.eldiario.net\/portal\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/eldiario.bolivia\/","https:\/\/x.com\/eldiario_net"]},{"@type":"Person","@id":"https:\/\/www.eldiario.net\/portal\/#\/schema\/person\/8b67770232aae58f106f1b9207b37de6","name":"Jeanette","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3ea2118a5f7dad2b7138b1187a6b7ee55f160b9968b66013c3a3ef39dd7e5798?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3ea2118a5f7dad2b7138b1187a6b7ee55f160b9968b66013c3a3ef39dd7e5798?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ea2118a5f7dad2b7138b1187a6b7ee55f160b9968b66013c3a3ef39dd7e5798?s=96&d=mm&r=g","caption":"Jeanette"},"sameAs":["https:\/\/www.eldiario.net\/portal"],"url":"https:\/\/www.eldiario.net\/portal\/author\/jeanette\/"}]}},"_links":{"self":[{"href":"https:\/\/www.eldiario.net\/portal\/wp-json\/wp\/v2\/posts\/182282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.eldiario.net\/portal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eldiario.net\/portal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eldiario.net\/portal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eldiario.net\/portal\/wp-json\/wp\/v2\/comments?post=182282"}],"version-history":[{"count":0,"href":"https:\/\/www.eldiario.net\/portal\/wp-json\/wp\/v2\/posts\/182282\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.eldiario.net\/portal\/wp-json\/wp\/v2\/media\/182283"}],"wp:attachment":[{"href":"https:\/\/www.eldiario.net\/portal\/wp-json\/wp\/v2\/media?parent=182282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eldiario.net\/portal\/wp-json\/wp\/v2\/categories?post=182282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eldiario.net\/portal\/wp-json\/wp\/v2\/tags?post=182282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}